Targeting both pathways simultaneously—through JAK-STAT inhibitors, TGF-β modulators, or metabolic interventions aimed at improving leptin sensitivity—could provide a novel therapeutic strategy for FS patients. The gene discussed is LEP; the disease is Feingold syndrome.